title: ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia.
abstract: The combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3, ATO) has been effective in obtaining high clinical complete remission (CR) rates in acute promyelocytic leukemia (APL), but the long-term efficacy and safety among newly diagnosed APL patients are unclear. In this retrospective study, total 45 newly diagnosed APL patients received ATRA/chemotherapy combination regimen to induce remission. Among them, 43 patients (95.6%) achieved complete remission (CR) after induction therapy, followed by ATO/ATRA/anthracycline-based chemotherapy sequential consolidation treatment with a median follow-up of 55 months. In these patients, the estimated overall survival (OS) and the relapse-free survival (RFS) were 94.4% ± 3.9% and 94.6 ± 3.7%, respectively. The toxicity profile was mild and reversible. No secondary carcinoma was observed. These results demonstrated the high efficacy and minimal toxicity of ATO/ATRA/anthracycline-based chemotherapy sequential consolidation treatment for newly diagnosed APL in long-term follow-up, suggesting a potential frontline therapy for APL.
authors.affiliation: Department of Hematology, Third Affiliated Hospital, Sun Yat-sen University, Sun Yat-sen Institute of Hematology, Sun Yat-sen University, Guangzhou, China.
authors.forename: Zi-Jie
authors.initials: ZJ
authors.lastname: Long
authors.affiliation: Department of Hematology, Third Affiliated Hospital, Sun Yat-sen University, Sun Yat-sen Institute of Hematology, Sun Yat-sen University, Guangzhou, China.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Hu
authors.affiliation: Department of Hematology, Third Affiliated Hospital, Sun Yat-sen University, Sun Yat-sen Institute of Hematology, Sun Yat-sen University, Guangzhou, China.
authors.forename: Xu-Dong
authors.initials: XD
authors.lastname: Li
authors.affiliation: Department of Hematology, Third Affiliated Hospital, Sun Yat-sen University, Sun Yat-sen Institute of Hematology, Sun Yat-sen University, Guangzhou, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: He
authors.affiliation: Department of Hematology, Third Affiliated Hospital, Sun Yat-sen University, Sun Yat-sen Institute of Hematology, Sun Yat-sen University, Guangzhou, China.
authors.forename: Ruo-Zhi
authors.initials: RZ
authors.lastname: Xiao
authors.affiliation: Department of Hematology, Third Affiliated Hospital, Sun Yat-sen University, Sun Yat-sen Institute of Hematology, Sun Yat-sen University, Guangzhou, China.
authors.forename: Zhi-Gang
authors.initials: ZG
authors.lastname: Fang
authors.affiliation: Department of Hematology, Third Affiliated Hospital, Sun Yat-sen University, Sun Yat-sen Institute of Hematology, Sun Yat-sen University, Guangzhou, China.
authors.forename: Dong-Ning
authors.initials: DN
authors.lastname: Wang
authors.affiliation: Department of Hematology, Third Affiliated Hospital, Sun Yat-sen University, Sun Yat-sen Institute of Hematology, Sun Yat-sen University, Guangzhou, China.
authors.forename: Jia-Jun
authors.initials: JJ
authors.lastname: Liu
authors.affiliation: Department of Hematology, Second Affiliated Hospital, Dalian Medical University, Dalian, China.
authors.forename: Jin-Song
authors.initials: JS
authors.lastname: Yan
authors.affiliation: Department of Hematology, Third Affiliated Hospital, Sun Yat-sen University, Sun Yat-sen Institute of Hematology, Sun Yat-sen University, Guangzhou, China.
authors.forename: Ren-Wei
authors.initials: RW
authors.lastname: Huang
authors.affiliation: Department of Hematology, Third Affiliated Hospital, Sun Yat-sen University, Sun Yat-sen Institute of Hematology, Sun Yat-sen University, Guangzhou, China.
authors.forename: Dong-Jun
authors.initials: DJ
authors.lastname: Lin
authors.affiliation: Department of Hematology, Third Affiliated Hospital, Sun Yat-sen University, Sun Yat-sen Institute of Hematology, Sun Yat-sen University, Guangzhou, China; Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
authors.forename: Quentin
authors.initials: Q
authors.lastname: Liu
mesh_terms: D000293:Adolescent; D000328:Adult; D018943:Anthracyclines / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D060830:Consolidation Chemotherapy / Q000009:adverse effects / Q000379:methods; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010087:Oxides / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction / Q000379:methods; D012189:Retrospective Studies; D016896:Treatment Outcome; D014212:Tretinoin / Q000008:administration & dosage / Q000009:adverse effects; D055815:Young Adult
chemical_list: D018943:Anthracyclines; D001152:Arsenicals; D010087:Oxides; D014212:Tretinoin; D000077237:Arsenic Trioxide